GGrantIndex
Sort

39,280 grants matching leukemia

Abnormalities/Signal Transduction/Hematopoietic Disease

$1,603,814
Dana-Farber Cancer Institute · P01 · FY2002 · DK

Flow Cytometric Analysis of Benign and Malignant Tumors

$1,603,346
Maryalice Stetler-Stevenson · Division Of Clinical Sciences - Nci · ZIC · FY2015 · CA

Targeted Therapy of B-cell Malignancies

$1,603,282
David M Goldenberg · Ctr For Molecular Medicine/Immunology · P01 · FY2007 · CA

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy

$1,602,982
Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2016 · HL

How the 3D architecture of the brain shapes cancer cell fate decisions

$1,602,000
Mariella Gruber Filbin · Dana-Farber Cancer Inst · DP2 · FY2021 · NS

Delaware/Christiana Care community Oncology Research Program

$1,600,001
Gregory A Masters · Christiana Care Health Services, Inc. · UG1 · FY2016 · CA

MOLECULAR GENETICS OF FANCONI ANEMIA

$1,598,800
Oregon Health And Science University · P01 · FY2000 · HL

Comprehensive dissection of the CLL genome & phenome to improve patient outcomes

$1,596,896
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2023 · CA

Comprehensive dissection of the CLL genome & phenome to improve patient outcomes

$1,596,329
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2022 · CA

Mouse Models for Understanding Host Responses to Intracellular Pathogens

$1,595,854
Ellen A Robey · University Of California Berkeley · P01 · FY2009 · AI

Alliance for Clinical Trials in Oncology Operations Center

$1,595,651
Monica M Bertagnolli · Brigham And Women'S Hospital · U10 · FY2016 · CA

Protein Structure

$1,593,257
Alexander Wlodawer · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Eosinophils and Eosinophil Activation in the Pathogenesis of Human Disease

$1,592,921
Amy Klion · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI

NHGRI/DIR Technology Transfer Program

$1,590,131
Daniel Kastner · National Human Genome Research Institute · ZIK · FY2011 · HG

ONCOGENE DEREGULATION/TUMOR SUPPRESSOR GENE LOSS IN CLL

$1,589,968
Thomas Jefferson University · P01 · FY2003 · CA

Development of Recombinant Toxins to Treat Hematologic Malignancies

$1,588,137
Robert Kreitman · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Metabolic regulation of T cell effector function and anti-tumor immunotherapy

$1,586,326
Naomi Taylor · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

INTERACTING FACTORS IN HEMATOPOIESIS AND LEUKEMIA

$1,585,639
Daniel G Tenen · Beth Israel Deaconess Medical Center · P01 · FY2006 · CA

Life and Longevity After Cancer (LILAC): The Women's Health Initiative Cancer Survivor Cohort

$1,584,592
Garnet L. Anderson · Fred Hutchinson Cancer Research Center · U01 · FY2019 · CA

Improving Retroviral Vectors for Gene Delivery

$1,584,584
University Of Southern California · P01 · FY2003 · CA

Genetic susceptibility to unrelated donor stem cell transplant-related mortality

$1,584,230
Theresa E Hahn · Roswell Park Cancer Institute Corp · R01 · FY2010 · HL

INTERACTING FACTORS IN HEMATOPOIESIS AND LEUKEMIA

$1,583,949
Daniel G Tenen · Beth Israel Deaconess Medical Center · P01 · FY2007 · CA

Flow Cytometric Analysis of Benign and Malignant Tumors

$1,583,756
Maryalice Stetler-Stevenson · Division Of Clinical Sciences - Nci · ZIC · FY2013 · CA

Therapeutic Opportunities for Pediatric Astrocytoma

$1,583,141
Rosalind A Segal · Dana-Farber Cancer Inst · P01 · FY2015 · CA

Mechanisms, Prevention and Treatment of Chronic Graft-vs.-Host Disease

$1,581,533
Corey S Cutler · Dana-Farber Cancer Inst · P01 · FY2019 · CA